A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 252
- Registration Number
- NCT06049017
- Locations
- 🇺🇸
Clinnova Research, Anaheim, California, United States
🇺🇸Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
🇺🇸I.H.S. Health. LLC, Kissimmee, Florida, United States
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 338
- Registration Number
- NCT06039189
- Locations
- 🇨🇦
Enverus Medical, Surrey, British Columbia, Canada
🇺🇸Total Dermatology, Birmingham, Alabama, United States
🇺🇸Cahaba Research Inc, Birmingham, Alabama, United States
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT06028438
- Locations
- 🇦🇷
Mautalen Salud e Investigacion, Caba, Argentina
🇺🇸Arizona Arthritis and Rheumatology Research PLLC, Phoenix, Arizona, United States
🇺🇸Newport Huntington Medical Group, Huntington Beach, California, United States
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 320
- Registration Number
- NCT05963074
- Locations
- 🇫🇷
CHU de Reims, Reims, France
🇭🇺Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz, Nyiregyhaza, Hungary
🇪🇸Hosp Univ Vall D Hebron, Barcelona, Spain
Global Patient Registry of Inherited Retinal Diseases
- Conditions
- Inherited Retinal Diseases
- Interventions
- Other: Standard of Care
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7000
- Registration Number
- NCT05957276
- Locations
- 🇦🇹
Kepler Universitatsklinikum GmbH, Linz, Austria
🇫🇷Hopitaux universitaires de Strasbourg, Srasbourg, France
🇩🇪Universitatsklinikum Bonn, Bonn, Germany
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05923073
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇧🇷Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro, Campinas, Brazil
🇧🇷Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro, Curitiba, Brazil
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
- Conditions
- Hemolytic Disease of the Fetus and Newborn
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05912517
- Locations
- 🇮🇱
Rabin Medical Center, Petah Tikva, Israel
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT05908734
- Locations
- 🇹🇷
Adana City Hospital, Adana, Turkey
🇹🇷Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey
🇹🇷Medicana International Izmir, Izmir, Turkey
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05896683
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
- Conditions
- Metastatic Castrate-sensitive Prostate Cancer
- Interventions
- Drug: Androgen-deprivation Therapy (ADT)
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 333
- Registration Number
- NCT05884398
- Locations
- 🇵🇱
Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O, Warszawa, Poland
🇩🇪Klinikum Augsburg, Augsburg, Germany
🇩🇪Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany